Liraglutide Pen Injector [Saxenda]

DRUG4 trials

Sponsors

University College, London, Woman's, General Committee of Teaching Hospitals and Institutes, Egypt, University of Chicago

Conditions

Acute Leukemia in RemissionLong COVIDLong Covid19Morbid ObesityMultiple SclerosisObeseObesityObesity Android

Early Phase 1

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

SuspendedNCT06171152

University of ChicagoAcute Leukemia in Remission, Long COVID, Long Covid19 +4

Start: 2024-01-26End: 2027-10-01Target: 30Updated: 2026-03-30

Phase 3

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

CompletedNCT03480022

Woman'sObesity Android, Polycystic Ovary Syndrome, Pre Diabetes

Start: 2018-09-26End: 2021-05-19Updated: 2021-06-07

Phase 4

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

CompletedNCT03341429

University College, LondonObesity

Start: 2018-08-22End: 2020-06-11Updated: 2020-11-05

Unknown Phase

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

General Committee of Teaching Hospitals and Institutes, EgyptMorbid Obesity

Start: 2022-03-10End: 2022-09-30Target: 60Updated: 2022-03-17

Related Papers

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery

JAMA Surgery2023-07-26132 citations

Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.

2022-06-1392 citations